Atrium spins out of Avidity, aiming to target rare heart diseases with RNA [Yahoo! Finance]
(RNAM)
Company Research
Source: Yahoo! Finance
This story was originally published on BioPharma Dive . To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter A newly formed spinout of recently acquired Avidity Biosciences debuted Friday with plans to pick up some of its predecessor's work. Called Atrium Therapeutics , the startup is emerging four months after the $12 billion buyout of Avidity at the hands of Novartis. It's led by Avidity's former Chief Program Officer Kathleen Gallagher, chaired by its ex-CEO Sarah Boyce and will develop RNA medicines for rare heart conditions — research that wasn't involved in the Novartis deal. Avidity was one of many companies working on ways to broaden the reach of RNA drugs , which have historically been limited to targets in the liver. Its technology was designed to send RNA medicines into hard-to-reach muscle tissue, and yielded a trio of medicines in late-stage development for three different neuromuscular conditions. The company went public at $
Show less
Read more
Impact Snapshot
Event Time:
RNAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNAM alerts
High impacting news events
Weekly update
A roundup of the hottest topics
RNAM
Sec Filings
- 2/27/26 - Form 4
- 2/27/26 - Form 4
- 2/27/26 - Form 4
- RNAM's page on the SEC website